📬 Lung/Head and Neck/Thymoma Intelligence Digest — Week 2026-W37
Daraxonrasib's phase 1-2 NSCLC data land in NEJM with 31-37% responses and 54% grade 3+ AEs, HARMONi-2 tops out on overall survival versus pembrolizumab, and updated AEGEAN outcomes keep EFS at HR 0.69 while OS stays immature.
⚡ TL;DR
📄 Publications
- Perioperative Durvalumab for Resectable Non-Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN Trial. — EFS benefit favoring durvalumab remained consistent with HR 0.69 (95% CI, 0.55 to 0.88) at a median follow-up of 25.9 months
- Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer. — 136 patients treated at doses of 300 mg or less were evaluated for safety and efficacy
- The Evolution of Immunotherapy Revolution in Lung Cancer: A 20-Year Perspective. — Immune checkpoint inhibition has been developed as monotherapy and in combinations across all stages of lung cancer
🐦 Twitter / 🦋 Bluesky
- Daraxonrasib's NEJM debut in RAS-mutant NSCLC: 31-37% responses against a 54% grade 3+ toxicity rate splits the field — Objective response was 31% at doses of 120 mg or less, 34% at 160-220 mg and 37% at 300 mg among 136 previously treated patients
- JTO's 20th-anniversary review takes stock of two decades of lung cancer immunotherapy — The review traces the transition from cytotoxic therapy to immune checkpoint inhibition as monotherapy and in combinations across all stages of disease
- HARMONi-2 tops out on overall survival: ivonescimab beats pembrolizumab monotherapy in PD-L1-positive NSCLC, with no numbers released — Akeso reports ivonescimab monotherapy significantly improved overall survival versus pembrolizumab in PD-L1-positive advanced NSCLC, after a prior PFS hazard ratio of 0.51 (p<0.0001)
- JTO systematic review quantifies ADC pulmonary toxicity, and it lands as two SCLC ADC trials head to the WCLC26 plenary — Any-grade pulmonary adverse events occurred in 30.9%, grade ≥3 in 6.9% and pneumonitis/ILD in 8.0%, with pulmonary AEs more frequent in SCLC than NSCLC (52.1% vs 22.5%) and pneumonitis more common in NSCLC than SCLC (12.1% vs 2.8%)
- KEYNOTE-A86 in JTO: subcutaneous pembrolizumab matches IV pharmacokinetics in first-line metastatic NSCLC — Subcutaneous pembrolizumab 380 mg Q3W showed non-inferior pharmacokinetics versus IV pembrolizumab 200 mg Q3W in first-line metastatic NSCLC with a similar safety profile
Full details below ↓
📄 What's Being Published
Perioperative Durvalumab for Resectable Non-Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN Trial. — Heymach John V et al., J Clin Oncol
At a median follow-up of 25.9 months, the event-free survival benefit favoring durvalumab remained consistent with HR 0.69 (95% CI, 0.55 to 0.88). DFS HR was 0.66 (95% CI, 0.47 to 0.92) and OS HR was 0.89 (95% CI, 0.70 to 1.14), both numerically favoring durvalumab. Maximum grade 3/4 adverse events during adjuvant treatment occurred in 15.4% of the durvalumab arm versus 10.6% in the placebo arm.
Clinical bottom line: With a second interim analysis now published, perioperative durvalumab holds a durable event-free survival advantage in resectable stage II–IIIB NSCLC, but overall survival remains immature and the trial still cannot say what the adjuvant half contributes.
Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer. — Arbour Kathryn C et al., N Engl J Med
Among 136 patients with NSCLC treated at doses of 300 mg or less, objective response rates were 31% at doses of 120 mg or less, 34% at doses of 160 to 220 mg, and 37% at a dose of 300 mg. Grade 3 or higher adverse events occurred in 54% of patients, with pneumonia (10%), diarrhea (9%), rash (8%), and anemia (5%) among the most common; four grade 5 adverse events occurred. RAS mutations occur in approximately 30% of patients with NSCLC, making this the most common oncogenic driver class addressed by the agent.
Clinical bottom line: Multiselective RAS(ON) inhibition is active in pretreated RAS-mutant NSCLC with responses above 30% across dose levels, but a 54% grade 3+ adverse event rate makes dose selection, not target validation, the deciding question for phase 3.
Matched targeted therapy use after broad genomic profiling in advanced Non-Small cell lung cancer. — Wang Xiao et al., J Natl Cancer Inst
Among 6620 patients, 2313 (89.6%) of 2582 with available first-line on-label options received them, representing a 10.4% underuse rate; by contrast, only 122 (27.7%) of 441 patients with guideline-concordant off-label options received them, a 72.3% underuse. Conversely, 238 (8.6%) of 3282 patients received matched but guideline-discordant off-label therapy, representing overuse of ineffective or unestablished treatments. Smoking history, squamous histology, and high PD-L1 expression were associated with lower targeted therapy receipt.
Clinical bottom line: Broad genomic profiling only helps if the result is acted on: first-line on-label matching is good, but later-line and off-label options are missed in a third to three quarters of eligible patients, and smokers with squamous or PD-L1-high tumors are the ones most often left untreated.
DNA and RNA EGFR Variant Allele Fractions and Clinical Outcomes in Lung Adenocarcinoma. — Silva Rodrigo Espinoza et al., J Thorac Oncol
VAF-based stratification identified a low-risk group with a 5-year relapse rate of 11%, independent of pathological stage (p<0.001), using multi-omics data from the Taiwan Cancer Moonshot Program (RFS, n=133; TKI, n=48) and an independent Singaporean validation cohort (RFS, n=54; TKI, n=17). High-risk patients had shorter PFS when TKI therapy was deferred until relapse (p=0.047).
Clinical bottom line: Combining DNA and RNA EGFR variant allele fractions separates early-stage patients whose 5-year relapse risk is only 11% from those who should not have adjuvant TKI deferred — a stratification that stage and binary mutation status cannot deliver.
The Evolution of Immunotherapy Revolution in Lung Cancer: A 20-Year Perspective. — Waissengrin Barliz et al., J Thorac Oncol
The understanding of tumor immunology and antigen presentation has enabled the development of immune checkpoint inhibition as monotherapy and in combinations across all stages of disease. The review covers key breakthroughs, clinical integration, limitations, and future directions related to immunotherapy for lung cancer.
Clinical bottom line: Twenty years on, immunotherapy is the cornerstone of lung cancer treatment across every stage, and this anniversary review is the reference account of how the transition from cytotoxic therapy happened and where it still falls short.
The impact of EGFR subtype combined with TP53 co-mutation status on survival outcomes with front-line osimertinib in non-small cell lung cancer (NSCLC). — Kim Hye Sung et al., Lung Cancer
Of 606 patients, 277 (46%) had EGFR L858R, 384 (63%) had TP53 co-mutations, and 186 (30.7%) had both. Patients with both markers showed especially short median rwPFS (10.1 vs. 21.4 months, HR 2.2, P<0.001) and OS (21.3 vs. 53.4 months, HR 2.3, P<0.001) compared with those with neither. Bearing L858R versus exon 19 deletion predicted inferior rwPFS (HR 1.4, P=0.001) and OS (HR 1.3, P=0.01), as did a TP53 co-mutation versus wildtype (rwPFS: HR 1.5, P<0.001; OS: HR 1.6, P<0.001).
Clinical bottom line: EGFR subtype and TP53 status should be read together before starting front-line osimertinib: patients with L858R plus TP53 mutation live a median 21.3 months versus 53.4 months, and are the group to route toward intensified regimens or trials.
Clinical outcomes and genomic features of uncommon EGFR exon 19 deletion subtypes in osimertinib-treated non-small cell lung cancer. — Hatano Hiroto et al., Lung Cancer
Patients with non-E746_A750del (n=25) had shorter PFS than those with E746_A750del (n=86), with median PFS of 14.3 versus 20.6 months (p<0.05). Among non-E746_A750del subtypes, L747_A750delinsP (n=4) showed a particularly poor prognosis, with median PFS of 3.5 versus 20.6 months (p<0.001) and median OS of 11.8 versus 48.5 months (p<0.001). Non-E746_A750del deletions were associated with higher RBM10 co-mutation rates, while L747_A750delinsP was characterized by frequent CDKN2A/B homozygous deletions and MYC amplifications.
Clinical bottom line: Exon 19 deletion is not one biomarker: reports should name the specific deletion, because L747_A750delinsP behaves like a high-risk subtype with median PFS of 3.5 months on osimertinib.
🗂 Every paper considered this week, including the ones that didn’t make it →
🗣️ What People Were Discussing This Week
How these are chosen: filtered for clinical relevance, grouped by the new development discussed, then ordered by engagement (bookmarks and reposts).
Daraxonrasib's NEJM debut in RAS-mutant NSCLC: 31-37% responses against a 54% grade 3+ toxicity rate splits the field
Among 136 previously treated patients, objective response rates ran from 31% at doses of 120 mg or less to 34% at 160–220 mg and 37% at 300 mg, while grade 3 or higher adverse events occurred in 54% of patients overall — including pneumonia, diarrhea, and rash. In the docetaxel-naive 160–220 mg subgroup, ORR was 42% with mPFS 8.3 months and mOS 16 months; grade ≥3 treatment-related adverse events were 25% at 160–220 mg and 45% at 300 mg, with four grade 5 adverse events. Patrick Forde reads the profile as high-grade toxicity in 54% including 2.9% deaths and PFS 8.3 months — not yet the pancreatic-cancer-scale breakthrough — while others, including Tejas Patil, call ORR 31% and mPFS 8 months impressive in this heavily pretreated population even as ~50% grade 3 events and deaths on study are flagged as a major issue for the class. With efficacy flat across dose levels and toxicity clearly not flat, the field is converging on 200 mg for phase 3 rather than the 300 mg pancreatic dose, and cost — cited at $39,800 per month for monotherapy — has entered the debate alongside the response and safety discussion.
Discussed by: @EladSharonMD, @FordePatrick, @OncBrothers, @TejasPatilMD, @OncoAlert, @StephenVLiu, @YGaritaonaindia, @BalazsHalmosMD, @Latinamd, @HHorinouchi
JTO's 20th-anniversary review takes stock of two decades of lung cancer immunotherapy
The review traces the development of immune checkpoint inhibition as monotherapy and in combinations across all stages of disease, covering key breakthroughs, clinical integration, limitations, and future directions. Across cancer types, adjuvant lung cancer immunotherapy studies have been inconsistent while neoadjuvant and perioperative approaches have been uniformly positive, with close monitoring for immune-related adverse events emphasized as a practical necessity. The 20-year vantage point frames the transition from cytotoxic therapy to checkpoint inhibition as a documented record of what changed and where gaps remain, rather than a settled field.
Discussed by: @HHorinouchi, @StephenVLiu
HARMONi-2 tops out on overall survival: ivonescimab beats pembrolizumab monotherapy in PD-L1-positive NSCLC, with no numbers released
Akeso reports that ivonescimab monotherapy significantly improved overall survival versus pembrolizumab in patients with PD-L1-positive advanced NSCLC, a pre-specified interim analysis involving 398 patients across 55 hospitals in China — the same trial that previously demonstrated a progression-free survival hazard ratio of 0.51 (p<0.0001) and median PFS of 11.1 versus 5.8 months. The topline announcement discloses no hazard ratio, no median OS, no event count, and no data cutoff; full OS results are expected as OA14.01 at WCLC26 on September 15. Clinicians note that the OS signal following a prior PFS HR of 0.51 with consistency across key subgroups is material news, but the press-release format and single-region enrollment mean the number to watch — OS in the PD-L1 ≥50% subgroup, which HARMONi-7 is testing globally — remains unreported.
Discussed by: @StephenVLiu, @BalazsHalmosMD, @YGaritaonaindia, @HHorinouchi, @M_Torasawa, @OncoAlert
JTO systematic review quantifies ADC pulmonary toxicity, and it lands as two SCLC ADC trials head to the WCLC26 plenary
A systematic review published in JTO reports any-grade pulmonary adverse events in 30.9% of patients receiving antibody-drug conjugates, grade ≥3 in 6.9%, and pneumonitis/ILD in 8.0%; pulmonary adverse events were more frequent in SCLC than NSCLC (52.1% vs. 22.5%), while pneumonitis was more common in NSCLC than SCLC (12.1% vs. 2.8%). The review arrives as two SCLC ADC studies — TAISHAN-302 (Tam-Peli, a B7-H3 ADC, versus topotecan) and ARTEMIS-008 (risvutatug rezetecan versus topotecan, described as the first reported positive phase III OS study of a B7-H3 ADC in SCLC) — appear in the WCLC26 Presidential Plenary. The senior author stresses that each ADC carries a distinct risk profile and that early recognition and prompt management of pulmonary toxicity are key to safe benefit, a point reinforced by the companion JTO review arguing that combining T-cell engagers with ADCs may produce deep and durable responses in extensive-stage SCLC.
Discussed by: @StephenVLiu, @ChristianRolfo, @HHorinouchi, @g_mountzios, @herbloong
KEYNOTE-A86 in JTO: subcutaneous pembrolizumab matches IV pharmacokinetics in first-line metastatic NSCLC
The phase III KEYNOTE-A86 trial randomized 531 patients with advanced NSCLC 2:1 to subcutaneous pembrolizumab 380 mg Q3W versus IV pembrolizumab 200 mg Q3W, meeting pharmacokinetic non-inferiority endpoints with no significant differences in efficacy or treatment-related adverse events between formulations. The similar safety profile and equivalent pharmacokinetics between routes put the operational and patient-preference case for a full infusion-center switch squarely on the table.
Discussed by: @OncoAlert, @StephenVLiu, @BalazsHalmosMD
HARMONi publishes in Lancet Oncology and its updated OS analysis is accepted at WCLC26 ahead of a November PDUFA date
The published HARMONi trial (n=438, 23% enrolled in the United States) reported PFS of 6.8 versus 4.4 months (HR 0.52) and OS of 16.8 versus 14.0 months (HR 0.79). The WCLC26 updated analysis reports ITT median OS of 16.8 versus 14.0 months (HR 0.76, 95% CI 0.61–0.95; nominal P=0.0151), with a Western cohort at 23.2 months follow-up showing 17.5 versus 14.0 months (HR 0.76, 0.52–1.10); grade ≥3 treatment-related adverse events were 51.4% versus 43.6%, and serious treatment-related adverse events were 28% versus 15%. With ITT OS now nominally positive and a 14 November PDUFA date for this second-line EGFR-mutant study, the Western confidence interval still crossing 1 is the central regulatory question.
Discussed by: @SandraOrtizCua1, @JacobPlieth, @ChandrakanthMv, @OncoAlert
JTO germline analysis: pathogenic variants in 8% of lung cancer patients, most often in DNA repair genes
An 8% rate of pathogenic germline variants among patients with lung cancer, concentrated most commonly in DNA repair genes, is the headline finding reviewed by Lee et al. in JTO. Despite predispositions to lung cancer being recognized more widely, pathogenic germline variant distribution remains incompletely characterized, a gap the analysis addresses but does not fully close, setting up a direct question about whether case-by-case referral remains appropriate at this prevalence.
Discussed by: @Latinamd, @jennifermarksmd
WCLC26 previews put MAVERICK's PCI question and the B7-H3 ADC readouts at the center of the SCLC agenda
The WCLC26 Presidential Symposium features three SCLC readouts drawing the most anticipation: MAVERICK (MRI±PCI), framed as a trial that could fundamentally change the role of prophylactic cranial irradiation in the MRI-surveillance era; TAISHAN-302, a phase III of the B7-H3 ADC Tam-Peli versus topotecan in relapsed SCLC; and ARTEMIS-008 (risvutatug rezetecan versus topotecan), described as the first reported positive phase III OS study of a B7-H3 ADC in SCLC. Radiation oncologists describe the moment as one week away from learning about the potential death of PCI, and the biomarker picture for B7-H3 is already being mapped: in an IMpower133/SKYSCRAPER-02 analysis, B7-H3 IHC expression above 80% was prevalent and consistent across four SCLC molecular subtypes, with no correlation to PD-L1 expression and no prognostic effect on PFS or OS.
Discussed by: @Latinamd, @ADesaiMD, @DrewMoghanaki
AbbVie's RC148 plus chemotherapy reports first-line NSCLC response rates that are being measured against ivonescimab
RC148 (ABBV-1480) plus chemotherapy in first-line NSCLC produced a squamous ORR of 90% — including a PD-L1<1% ORR of 93% — and a non-squamous ORR of 76%, with a PD-L1<1% ORR of 71% in that setting. Separately at WCLC26, a phase 2 of the PD-1/VEGF bispecific JS207 plus chemotherapy in unresectable stage III NSCLC converted 52.4% (22/42) of patients to surgery, with pCR in 54.5% (12/22) and MPR in 72.7% (16/22), at the cost of JS207-related grade ≥3 treatment-emergent adverse events in 45.2% and serious adverse events in 19.0%.
Discussed by: @JacobPlieth, @OncoAlert
SOLARA at WCLC26: the macrocyclic EGFR TKI BH-30643 shows activity against C797S and T790M resistance mutations
Among 65 patients with 86 secondary EGFR resistance mutations (47 C797S, 24 T790M), BH-30643 produced RECIST responses in 43% and tumor shrinkage in 86% of the C797S-evaluable group (n=28), with on-treatment ctDNA clearance of 16/21 (76%) for C797S and 8/13 (62%) for T790M; median follow-up was only 3 months. The FDA has granted BH-30643 fast track designation in EGFR C797S-positive NSCLC. The brevity of follow-up behind a 43% C797S response rate is the central tension in translating these data into post-osimertinib sequencing decisions today.
Discussed by: @HHorinouchi, @OncoAlert, @OncLive
FDA breakthrough designation for JBS-003, a hypoxia PET tracer aimed at radiation de-escalation in HPV-positive oropharyngeal cancer
The FDA granted breakthrough therapy designation to JBS-003, an investigational PET imaging tracer developed at MSK Cancer Center intended to identify tumor hypoxia and guide radiation de-escalation in patients with HPV-positive oropharyngeal carcinoma. Radiation oncologists involved in the associated phase 3 describe it as enrolling rapidly and as having more practice-changing potential than any trial in which they have participated, setting the stage for a prospective test of hypoxia-guided selection in a disease where prior de-escalation attempts have failed on selection rather than concept.
Discussed by: @OncLive, @seanmmcbride
SANOVO: savolitinib plus osimertinib improves first-line PFS in EGFR-mutant, MET-overexpressing NSCLC
SANOVO, a phase III trial comparing osimertinib plus savolitinib versus osimertinib alone in treatment-naive EGFR-mutated NSCLC with MET overexpression, reported a statistically significant and highly clinically meaningful improvement in PFS. The result — savolitinib plus osimertinib significantly improved PFS versus osimertinib alone in locally advanced or metastatic EGFR-mutant, MET-overexpressing NSCLC — positions MET overexpression as a prospective stratification factor that may need to be assessed at diagnosis.
Discussed by: @HHorinouchi, @CancerNetwrk, @OncLive
COPERNICUS: prophylaxis-supported subcutaneous amivantamab plus lazertinib cuts the toxicity that dogged MARIPOSA
With enhanced dermatologic and VTE prophylaxis in COPERNICUS, rash was 28%, infusion-related reactions 12%, and VTE 12% — all numerically lower than in MARIPOSA — and amivantamab discontinuation due to adverse events was only 7%, compared with 34% in MARIPOSA. The presenter frames the result as placing supportive care at the center of advanced EGFR-mutated lung cancer management, directly opening the question of whether the tolerability problems seen in MARIPOSA reflect a supportive-care failure rather than an intrinsic drug property.
Discussed by: @HHorinouchi, @BalazsHalmosMD
Red Journal commentary pushes back on pathologic response and proton survival signals in head and neck cancer
A commentary in the International Journal of Radiation Oncology Biology Physics argues that a strong surrogate is not the same as a practice-changing endpoint, that pathologic response should not yet drive radiation omission in HNSCC, and that the late OS signal with protons may be entangled with access-to-care and salvage-treatment confounding. The authors extend their position to induction and post-operative immunotherapy in HNSCC alongside the proton debate, inviting review of their full reasoning on both.
Discussed by: @seanmmcbride, @CTuscanoMD
🔥 Top Ranked Tweets
Neeraj Agarwal, MD, FASCO @neerajaiims
RT @OncoAlert: This week's OncoAlert 🚨 Newsletter is packed with practice-changing data:
REGISTER TO GET IT 👉 https://t.co/NhtuRoIyO3
NOW OUT!
✅️ FDA 🇺🇸 approves daraxonrasib — first-in-class RAS inhibitor for metastatic #PancreaticCancer
✅️FDA approves zanidatamab-hrii + tislelizumab-jsgr for HER2+ gastric/GEJ/esophageal cancer
✅️Merck & Moderna's INTerpath-001 hits its endpoints — mRNA neoantigen therapy + pembrolizumab in resected #melanoma
✅️5-year KEYNOTE-671 data confirms durable benefit of perioperative pembrolizumab in resectable NSCLC #LungCancer
✅️Dose-escalated radiotherapy (80 Gy) improves 10-year PFS in high-risk #ProstateCancer (GETUG AFU 18)
...and more, curated by practicing oncologists — for colleagues, by colleagues.
Get it in your inbox every week!
@matteolambe
@aftimosp
@E_de_Azambuja
@DrSGraff
@ErikaHamilton9
@double_whammied
@maryam_lustberg
@raalbany
@hoperugo
@stolaney1
@LoiSher
@JaniceTNBCmets
@montypal
@DrDanielHeng
@apolo_andrea
@DrChoueiri
@PGrivasMDPhD
@TiansterZhang
@neerajaiims
@amerseburger
@sonpavde
@drenriquegrande
@tompowles1
@cdanicas
@nataliagandur
@realbowtiedoc
@Onco_Cifu88
@scocmem
@FernandoOnco
@ElisaAgostinett
@to_be_elizabeth
@Erman_Akkus
@MarioBalsaMD
@DrMirallas
@GIMedOnc
@UOzkerim
@DrRishabhOnco
@PaulJiL
@DaisukeKotani
@DraMartinezLago
@p_ciracimd
@BenWestphalen
@CentralParkWMD
@graokane
@amandaNizamMD
@DrVilmaPBarcia
🔖 2 ❤️ 31 🔁 16 👁 7,549
Dr. Estela Rodriguez @Latinamd
RT @OncoAlert: This week's OncoAlert 🚨 Newsletter is packed with practice-changing data:
REGISTER TO GET IT 👉 https://t.co/NhtuRoIyO3
NOW OUT!
✅️ FDA 🇺🇸 approves daraxonrasib — first-in-class RAS inhibitor for metastatic #PancreaticCancer
✅️FDA approves zanidatamab-hrii + tislelizumab-jsgr for HER2+ gastric/GEJ/esophageal cancer
✅️Merck & Moderna's INTerpath-001 hits its endpoints — mRNA neoantigen therapy + pembrolizumab in resected #melanoma
✅️5-year KEYNOTE-671 data confirms durable benefit of perioperative pembrolizumab in resectable NSCLC #LungCancer
✅️Dose-escalated radiotherapy (80 Gy) improves 10-year PFS in high-risk #ProstateCancer (GETUG AFU 18)
...and more, curated by practicing oncologists — for colleagues, by colleagues.
Get it in your inbox every week!
@matteolambe
@aftimosp
@E_de_Azambuja
@DrSGraff
@ErikaHamilton9
@double_whammied
@maryam_lustberg
@raalbany
@hoperugo
@stolaney1
@LoiSher
@JaniceTNBCmets
@montypal
@DrDanielHeng
@apolo_andrea
@DrChoueiri
@PGrivasMDPhD
@TiansterZhang
@neerajaiims
@amerseburger
@sonpavde
@drenriquegrande
@tompowles1
@cdanicas
@nataliagandur
@realbowtiedoc
@Onco_Cifu88
@scocmem
@FernandoOnco
@ElisaAgostinett
@to_be_elizabeth
@Erman_Akkus
@MarioBalsaMD
@DrMirallas
@GIMedOnc
@UOzkerim
@DrRishabhOnco
@PaulJiL
@DaisukeKotani
@DraMartinezLago
@p_ciracimd
@BenWestphalen
@CentralParkWMD
@graokane
@amandaNizamMD
@DrVilmaPBarcia
🔖 2 ❤️ 31 🔁 16 👁 7,551
OncoAlert @OncoAlert
This week's OncoAlert 🚨 Newsletter is packed with practice-changing data:
REGISTER TO GET IT 👉 https://t.co/NhtuRoIyO3
NOW OUT!
✅️ FDA 🇺🇸 approves daraxonrasib — first-in-class RAS inhibitor for metastatic #PancreaticCancer
✅️FDA approves zanidatamab-hrii + tislelizumab-jsgr for HER2+ gastric/GEJ/esophageal cancer
✅️Merck & Moderna's INTerpath-001 hits its endpoints — mRNA neoantigen therapy + pembrolizumab in resected #melanoma
✅️5-year KEYNOTE-671 data confirms durable benefit of perioperative pembrolizumab in resectable NSCLC #LungCancer
✅️Dose-escalated radiotherapy (80 Gy) improves 10-year PFS in high-risk #ProstateCancer (GETUG AFU 18)
...and more, curated by practicing oncologists — for colleagues, by colleagues.
Get it in your inbox every week!
@matteolambe
@aftimosp
@E_de_Azambuja
@DrSGraff
@ErikaHamilton9
@double_whammied
@maryam_lustberg
@raalbany
@hoperugo
@stolaney1
@LoiSher
@JaniceTNBCmets
@montypal
@DrDanielHeng
@apolo_andrea
@DrChoueiri
@PGrivasMDPhD
@TiansterZhang
@neerajaiims
@amerseburger
@sonpavde
@drenriquegrande
@tompowles1
@cdanicas
@nataliagandur
@realbowtiedoc
@Onco_Cifu88
@scocmem
@FernandoOnco
@ElisaAgostinett
@to_be_elizabeth
@Erman_Akkus
@MarioBalsaMD
@DrMirallas
@GIMedOnc
@UOzkerim
@DrRishabhOnco
@PaulJiL
@DaisukeKotani
@DraMartinezLago
@p_ciracimd
@BenWestphalen
@CentralParkWMD
@graokane
@amandaNizamMD
@DrVilmaPBarcia
🔖 2 ❤️ 31 🔁 16 👁 7,549
Journal of Clinical Oncology @JCO_ASCO
Therapy for Stage IV Non-Small Cell Lung Cancer with Driver Alterations: ASCO Living Guideline, Version 2026.3.3.
Read the full article. https://t.co/4fLMu8TkZQ
#NSCLC
🔖 1 ❤️ 10 🔁 4 👁 2,274
Elad Sharon @EladSharonMD
RT @JCO_ASCO: Therapy for Stage IV Non-Small Cell Lung Cancer with Driver Alterations: ASCO Living Guideline, Version 2026.3.3.
Read the full article. https://t.co/4fLMu8TkZQ
#NSCLC
🔖 1 ❤️ 10 🔁 4 👁 2,274
Stephen V Liu, MD @StephenVLiu
Results from E4512 @LancetRespirMed - adjuvant crizotinib for pts with resected ALK+ NSCLC did not improve DFS or OS. Effective adjuvant targeted therapy must be potent, CNS active, and well tolerated. Alectinib / ensartinib remain the standard.
https://t.co/ChpNn2swiz
🔖 7 ❤️ 25 🔁 5 👁 2,933
Elad Sharon @EladSharonMD
RT @Tony_Calles: Hot off the press! 📰 @TheLancetOncol #LCSM
Proud of the contribution of Hospital Gregorio Marañón, with our Medical Oncology and Clinical Research teams, to this important publication.
#Ivonescimab is a first-in-class bispecific immunotherapy with the potential to overcome some of the limitations of first-generation anti-PD-1/PD-L1 inhibitors, which revolutionized lung cancer care more than a decade ago.
This is the first global phase III trial to demonstrate clinically meaningful activity in this challenging setting, addressing a major unmet need for patients with EGFR-mutant lung cancer who have progressed after EGFR-targeted therapies.
I would especially like to thank the patients and their families, whose generous participation in clinical research makes advances like this possible.
Many more developments to come in this rapidly evolving field! 🚀
https://t.co/KdFSujSojS
🔖 4 ❤️ 31 🔁 7 👁 1,973
Sandra Ortiz-Cuaran @SandraOrtizCua1
RT @LeXiuning: 😜 Are we ready for the era of #PD1×VEGF #bispecific immunotherapy? 📖 Now online in #LancetOncology: #HARMONi — #ivonescimab plus chemotherapy in patients with #EGFR-mutant #NSCLC after progression on EGFR TKI therapy.
👉 First global randomized phase 3 study of a PD1×VEGF bispecific antibody
N = 438, with 23% of patients enrolled in the United States
👉 Progression-free survival: 6.8 vs 4.4 months, HR 0.52
👉 Overall survival: 16.8 vs 14.0 months, HR 0.79
👉 Encouraging evidence of protection against CNS progression
💡 HARMONi represents an important step in evaluating the potential of simultaneously targeting PD-(L1)1 and VEGF. I hope this will be the first of many positive global studies exploring PD-(L)1 × VEGF approaches for patients with lung cancer and other solid tumors. https://t.co/o76uqb8uQQ
❤️ my global col-investigators, @Tony_Calles @delvysra @MNagasaka @DrSanjayPopat @nicogirardcurie, Drs. Passaro, Cappuzzo, Zhang, and many others ❤️
🔖 8 ❤️ 70 🔁 17 👁 3,751
ClinicalOncologyNews @ClinOncNews
FDA approves zidesamtinib (Jideytro) for adults with locally advanced or metastatic ROS1-positive NSCLC after prior ROS1 TKI therapy. In ARROS-1, the ORR was 44%, with many responses lasting ≥12 months: https://t.co/66FEsAxiy9 #LungCancer https://t.co/6RrmThBW2Y
🔖 0 ❤️ 0 🔁 0 👁 90
OncoAlert @OncoAlert
RT @HHorinouchi: 🔥SANOVO: "Statistically significant and highly clinically meaningful improvement in PFS"
🆙 @hutchmed @AstraZeneca
👥Patients: Treatment-naïve, locally advanced or metastatic EGFR-mutated (EGFRm) NSCLC with MET overexpression
3⃣Phase III
⚖️Osimertinib + Savolitinib
⚖️Osimertinib alone
🔢NCT05009836
#LCSM @OncoAlert @Larvol @EGFRResisters
🔗 https://t.co/HLqBnnETdG
🔗 https://t.co/iwUkquqQUa
🔖 12 ❤️ 18 🔁 8 👁 2,813
OncoAlert @OncoAlert
RT @OncoAlert: This week's OncoAlert 🚨 Newsletter is packed with practice-changing data:
REGISTER TO GET IT 👉 https://t.co/NhtuRoIyO3
NOW OUT!
✅️ FDA 🇺🇸 approves daraxonrasib — first-in-class RAS inhibitor for metastatic #PancreaticCancer
✅️FDA approves zanidatamab-hrii + tislelizumab-jsgr for HER2+ gastric/GEJ/esophageal cancer
✅️Merck & Moderna's INTerpath-001 hits its endpoints — mRNA neoantigen therapy + pembrolizumab in resected #melanoma
✅️5-year KEYNOTE-671 data confirms durable benefit of perioperative pembrolizumab in resectable NSCLC #LungCancer
✅️Dose-escalated radiotherapy (80 Gy) improves 10-year PFS in high-risk #ProstateCancer (GETUG AFU 18)
...and more, curated by practicing oncologists — for colleagues, by colleagues.
Get it in your inbox every week!
@matteolambe
@aftimosp
@E_de_Azambuja
@DrSGraff
@ErikaHamilton9
@double_whammied
@maryam_lustberg
@raalbany
@hoperugo
@stolaney1
@LoiSher
@JaniceTNBCmets
@montypal
@DrDanielHeng
@apolo_andrea
@DrChoueiri
@PGrivasMDPhD
@TiansterZhang
@neerajaiims
@amerseburger
@sonpavde
@drenriquegrande
@tompowles1
@cdanicas
@nataliagandur
@realbowtiedoc
@Onco_Cifu88
@scocmem
@FernandoOnco
@ElisaAgostinett
@to_be_elizabeth
@Erman_Akkus
@MarioBalsaMD
@DrMirallas
@GIMedOnc
@UOzkerim
@DrRishabhOnco
@PaulJiL
@DaisukeKotani
@DraMartinezLago
@p_ciracimd
@BenWestphalen
@CentralParkWMD
@graokane
@amandaNizamMD
@DrVilmaPBarcia
🔖 2 ❤️ 37 🔁 19 👁 11,935
Hidehito HORINOUCHI @HHorinouchi
🔥SANOVO: "Statistically significant and highly clinically meaningful improvement in PFS"
🆙 @hutchmed @AstraZeneca
👥Patients: Treatment-naïve, locally advanced or metastatic EGFR-mutated (EGFRm) NSCLC with MET overexpression
3⃣Phase III
⚖️Osimertinib + Savolitinib
⚖️Osimertinib alone
🔢NCT05009836
#LCSM @OncoAlert @Larvol @EGFRResisters
🔗 https://t.co/HLqBnnETdG
🔗 https://t.co/iwUkquqQUa
[Quoting @HHorinouchi: 🔄 #ASCO25 REVIEW🔁
☑️#LCSM Oral, Mets
🔥SACHI: Savolitinib combined with osimertinib vs chemo in EGFR-m and MET-amp NSCLC after PD on EGFR TKI
🎙️ Dr. Shun Lu
🎯Saco+Osi/Chemo, ORR 63.2 vs. 36.2%, mPFS 8.2 vs. 4.5m (HR 0.34)
@OncoAlert @ASCO @larvol
https://t.co/jhgJI1Z8hP https://t.co/5p8UMsap71]
🔖 12 ❤️ 18 🔁 8 👁 2,813
OncLive.com @OncLive
🫁 Improved PFS was shown for T-DXd in first-line HER2-mutant NSCLC, according to data from the phase 3 DESTINY-Lung04 trial.
Full details 📰: https://t.co/s3PW59VhDY
#oncology #lcsm
🔖 0 ❤️ 2 🔁 0 👁 1,084
Targeted Oncology @TargetedOnc
🔬 Ivonescimab extends OS and doubles PFS versus pembrolizumab in first-line PD‑L1+ metastatic #NSCLC, with manageable safety.
Read more: https://t.co/xtnzLXUoQJ
#LungCancer #ClinicalTrials #CancerTreatment
🔖 0 ❤️ 0 🔁 0 👁 149
OncoAlert @OncoAlert
NEWS from Industry: HARMONI-2 Update in #NSCLC
Source businessWire
🚨 Ivonescimab shows an overall survival benefit in advanced NSCLC
Akeso reports positive Phase III HARMONi-2 results showing that ivonescimab monotherapy significantly improved overall survival vs. pembrolizumab in patients with PD-L1-positive advanced non-small cell lung cancer.
The study previously demonstrated a significant progression-free survival benefit, with a hazard ratio of 0.51 (p<0.0001).
Ivonescimab is already approved in China🇨🇳 for certain NSCLC indications, while it remains investigational in the U.S.🇺🇸 and Europe🇪🇺
#NSCLC #LungCancer #Oncology #Immunotherapy #Biotech #ClinicalTrials
https://t.co/lKG1xViNnS
Pinging our faculty
@peters_solange
@christine_lovly
@GlopesMd
@DrSanjayPopat
@StephenVLiu
@HenningWillers
@HHorinouchi
@BRicciutiMD
@PercyLeeMD
@jillfeldman4
bensolomon1
@Latinamd
@DrJNaidoo
@barlesi
@UOzkerim
@FernandoOnco
@DrMirallas
@VanitaNoronha
@NarjustFlorezMD
@MartinReck2
@realbowtiedoc
@FernandoOnco
@ElisaAgostinett
@to_be_elizabeth
@MarioBalsaMD
@BRicciutiMD
@HHorinouchi
@UOzkerim
@p_ciracimd
@AmandaNizamMD
@scocmem
@DrVilmaPBarcia
@DraMartinezLago
@DrMirallas
@nataliagandur
@GIMedOnc
@DaisukeKotani
🔖 0 ❤️ 15 🔁 6 👁 759
Prepared by Rafael Santana-Davila, M.D. Questions or feedback? Just reply to this email.
Disclaimer: This digest is AI-generated. Content may contain errors -- always verify with original sources.
Know a colleague who would find this useful? Just forward them this email.